Recently, in Wang’s study (87), NSCLC-like (without TP53/RB1 co-alterations) LCNEC patients were also attempted to receive NSCLC plus SCLC chemotherapy regimen. This evidence concerns the gene TP53 and non-small cell lung carcinoma.